OTCMKTS:ANTH Anthera Pharmaceuticals (ANTH) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChart About Anthera Pharmaceuticals Stock (OTCMKTS:ANTH) Get ANTH alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume54 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Anthera Pharmaceuticals was a U.S.-based biopharmaceutical company focused on developing therapies for serious inflammatory, autoimmune and gastrointestinal diseases. The company operated primarily as a clinical-stage drug developer and did not establish a broad commercial product portfolio. Its principal programs included varespladib, an investigational treatment intended to address inflammatory conditions, and Sollpura (liprotamase), an oral pancreatic enzyme replacement therapy for people with exocrine pancreatic insufficiency. Sollpura was designed to help patients digest and absorb nutrients more effectively. Anthera conducted its development activities mainly in the United States and pursued regulatory approval through clinical trials. Following setbacks involving its late-stage programs, the company reduced operations and pursued restructuring proceedings, and it is no longer known as an active, commercial-stage pharmaceutical business.AI Generated. May Contain Errors. Read More Receive ANTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anthera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANTH Stock News HeadlinesAnthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) Short Interest Up 111.4% in AugustSeptember 14, 2026 | americanbankingnews.comSpaceX Lost $1 Trillion In A Week. So Why Did Bond Investors Rush To Lend It $20 Billion?June 23, 2026 | benzinga.comBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.September 24 at 1:00 AM | Decentralized Masters (Ad)ANTH Anthera Pharmaceuticals, Inc.April 24, 2025 | seekingalpha.comMACK - Merrimack Pharmaceuticals, Inc.June 28, 2023 | finance.yahoo.comIndustry Research Report on Cystic Fibrosis Drugs Market Share and Industrial Overview till 2030May 16, 2023 | marketwatch.comSystemic Lupus Erythematosus (SLE) Drugs Market Updates: 2023-2030 ForecastMay 16, 2023 | marketwatch.com2023-2030 Vasculitis Treatment Market Size (Growth and Outlook) includes Main Business Overview | with [124 Pages]May 5, 2023 | marketwatch.comSee More Headlines ANTH Stock Analysis - Frequently Asked Questions How were Anthera Pharmaceuticals' earnings last quarter? Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) announced its quarterly earnings data on Monday, March, 5th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.09. When did Anthera Pharmaceuticals' stock split? Shares of Anthera Pharmaceuticals reverse split on Monday, May 1st 2017.The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of Anthera Pharmaceuticals? Shares of ANTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anthera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anthera Pharmaceuticals investors own include Ocular Therapeutix (OCUL), Novavax (NVAX), Bristol Myers Squibb (BMY), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO). Company Calendar Last Earnings3/05/2018Today9/23/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:ANTH CIK1316175 Webwww.anthera.com Phone(410) 350-1839Fax510-856-5597Employees21Year Founded2004Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.43 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:ANTH) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredEveryone remembers January's silver spike. Then what?Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anthera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anthera Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
